Antiviral Drugs Market, By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others), By Type (Branded and Generics), By Application (HIV, Hepatitis, Herpes, Influenza, and Others),

Global antiviral drugs market is estimated to be valued at USD 67.04 Bn in 2025 and is expected to exhibit a CAGR of 5.3% during the forecast period (2025-2032). The global antiviral drugs market has been witnessing steady growth over the past few years. Antiviral drugs, also known as antiviral agents or anti-infective medications, are a class of medication used specifically for treating infections caused by viruses. They work by inhibiting the production of viruses or preventing their spread in the body. Rising prevalence of viral diseases such as HIV/AIDS, hepatitis, influenza and others have been fueling demand for antiviral medications globally. According to the World Health Organization (WHO), around 36.7 million people were living with HIV worldwide in 2020.

Market Dynamics:

The global antiviral drugs market growth is driven by the growing incidence of viral infections and pandemics. The emergence of COVID-19 pandemic has further augmented the demand for antiviral drugs for treatment. Favorable government support and rising expenditure on healthcare facilities are also propelling the market growth. However, high costs associated with drug discovery and development as well as stringent regulatory approvals are restraining the market expansion. On the positive side, increasing R&D for developing novel antiviral therapeutics is expected to create lucrative opportunities for players in the coming years.

Key Features of the Study:

• This report provides an in-depth analysis of the global antiviral drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global antiviral drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes AbbVie Inc., GSK plc, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Cipla, Aurobindo Pharma, Gilead Sciences, Inc., Merck & Co., Inc., Zydus Group, Atea Pharmaceuticals, Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Torrent Pharmaceuticals Ltd., Arbutus Biopharma, Divi's Laboratories Limited, RedHill Biopharma Ltd., ViiV Healthcare Pty Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global antiviral drugs market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antiviral drugs market.

• By Drug Class:
• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Others
• By Type:
• Branded
• Generics
• By Application:
• HIV
• Hepatitis
• Herpes
• Influenza
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• AbbVie Inc.
• GSK plc
• Reddy's Laboratories Ltd.
• Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Cipla
• Aurobindo Pharma
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Zydus Group
• Atea Pharmaceuticals
• Johnson & Johnson Services, Inc.
• Sun Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Torrent Pharmaceuticals Ltd.
• Arbutus Biopharma
• Divi's Laboratories Limited
• RedHill Biopharma Ltd.
• ViiV Healthcare Pty Ltd.